{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:35:43Z","timestamp":1776681343037,"version":"3.51.2"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02306","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T04:53:20Z","timestamp":1569905600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Therapeutic Modulation of the Complement System in Kidney Transplantation: Clinical Indications and Emerging Drug Leads"],"prefix":"10.3389","volume":"10","author":[{"given":"Vasishta S.","family":"Tatapudi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis\u2013a new look at an old entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1172\/JCI72273","article-title":"Complement as a multifaceted modulator of kidney transplant injury","volume":"124","author":"Cravedi","year":"2014","journal-title":"J Clin. Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat Rev Drug Disc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","article-title":"New insights into the immune functions of complement","volume":"19","author":"Reis","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/ni.3858","article-title":"Novel mechanisms and functions of complement","volume":"18","author":"Hajishengallis","year":"2017","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrd2369","article-title":"Eculizumab","volume":"6","author":"Parker","year":"2007","journal-title":"Nat Rev Drug Disc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0805538","article-title":"Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema","volume":"363","author":"Zuraw","year":"2010","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1056\/NEJM198502283120905","article-title":"The quality of life of patients with end-stage renal disease","volume":"312","author":"Evans","year":"1985","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra0902927","article-title":"Rejection of the kidney allograft","volume":"363","author":"Nankivell","year":"2010","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJM196904032801401","article-title":"Significance of the positive crossmatch test in kidney transplantation","volume":"280","author":"Patel","year":"1969","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","article-title":"Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era","volume":"4","author":"Meier-Kriesche","year":"2004","journal-title":"Am J Transpl"},{"key":"B17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/TP.0b013e3181e065de","article-title":"Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure","volume":"90","author":"Gaston","year":"2010","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1365-2249.1991.tb02954.x","article-title":"Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection","volume":"86","author":"Feucht","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrneph.2012.212","article-title":"The role of complement in antibody-mediated rejection in kidney transplantation","volume":"8","author":"Stegall","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1681\/ASN.V12122807","article-title":"Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch","volume":"12","author":"Karpinski","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1440-1797.2008.01074.x","article-title":"Review article: luminex technology for HLA antibody detection in organ transplantation","volume":"14","author":"Tait","year":"2009","journal-title":"Nephrology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nrneph.2012.81","article-title":"The impact of donor-specific anti-HLA antibodies on late kidney allograft failure","volume":"8","author":"Loupy","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41581-018-0039-x","article-title":"HLA in transplantation","volume":"14","author":"Montgomery","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40472-017-0148-7","article-title":"Pharmacologic Complement Inhibition in Clinical Transplantation","volume":"4","author":"Tatapudi","year":"2017","journal-title":"Curr Transpl Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 Inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study","volume":"16","author":"Viglietti","year":"2016","journal-title":"Am J Transpl"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am J Transpl"},{"key":"B29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00007890-200009270-00006","article-title":"Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients","volume":"70","author":"Montgomery","year":"2000","journal-title":"Transplantation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/j.1600-6143.2011.03525.x","article-title":"Summary of FDA antibody-mediated rejection workshop","volume":"11","author":"Archdeacon","year":"2011","journal-title":"Am J Transpl"},{"key":"B31","unstructured":"NCT01895127"},{"key":"B32","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/TP.0000000000000298","article-title":"Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation","volume":"98","author":"Orandi","year":"2014","journal-title":"Transplantation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transpl"},{"key":"B34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial","volume":"18","author":"Eskandary","year":"2018","journal-title":"Am J Transpl"},{"key":"B35","unstructured":"EaSoHP-dC-eIaa-otSoCftToRAMRAiART"},{"key":"B36","unstructured":""},{"key":"B37","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1111\/ajt.13273","article-title":"An anti-C1s monoclonal, TNT003, inhibits complement activation induced by antibodies against HLA","volume":"15","author":"Thomas","year":"2015","journal-title":"Am J Transpl"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1111\/ajt.14256","article-title":"Effect of the anti-C1s humanized antibody TNT009 and its parental mouse variant TNT003 on HLA antibody-induced complement activation-a preclinical in vitro study","volume":"17","author":"Wahrmann","year":"2017","journal-title":"Am J Transpl"},{"key":"B39","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nrneph.2017.128","article-title":"IdeS to desensitize organ allograft recipients","volume":"13","author":"B\u00f6hmig","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1600-6143.2010.03340.x","article-title":"Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches","volume":"11","author":"Cecka","year":"2011","journal-title":"Am J Transpl"},{"key":"B41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/ajt.14124","article-title":"OPTN\/SRTR 2015 annual data report: kidney","volume":"17","author":"Hart","year":"2017","journal-title":"Am J Transpl"},{"key":"B42","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1056\/NEJMoa1508380","article-title":"Survival Benefit with kidney transplants from HLA-incompatible live donors","volume":"374","author":"Orandi","year":"2016","journal-title":"N Engl J Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/j.1600-6143.2008.02441.x","article-title":"Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation","volume":"8","author":"Burns","year":"2008","journal-title":"Am J Transpl"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transpl"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am J Transpl"},{"key":"B47","unstructured":"Alexion Pharmaceuticals"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15364","article-title":"Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial","author":"Marks","year":"2019","journal-title":"Am J Transpl"},{"key":"B49","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1681\/ASN.2017050589","article-title":"Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment","volume":"29","author":"Lefaucheur","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of c3 glomerulopathy: a case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2215\/CJN.00050505","article-title":"Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background","volume":"1","author":"Bresin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"98","author":"Matar","year":"2014","journal-title":"Transplantation"},{"key":"B56","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B57","unstructured":""},{"key":"B58","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/path.4635","article-title":"The role of genetically engineered pigs in xenotransplantation research","volume":"238","author":"Cooper","year":"2016","journal-title":"J Pathol"},{"key":"B59","unstructured":""},{"key":"B60","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri2099","article-title":"Xenotransplantation: current status and a perspective on the future","volume":"7","author":"Yang","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e12419","DOI":"10.1111\/xen.12419","article-title":"IXA Honorary Member Lecture, 2017: the long and winding road to tolerance","volume":"25","author":"Sykes","year":"2018","journal-title":"Xenotransplantation"},{"key":"B62","unstructured":"SykesM iBiology. The Immune Response to Allo- and Xenotransplantation: Part 3-Xenotransplantation"},{"key":"B63","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.1073\/pnas.0307819101","article-title":"Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations","volume":"101","author":"Kolber-Simonds","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B64","first-page":"604","article-title":"Xenotransplantation of hDAF-transgenic swine hearts","volume":"124","author":"Schmoeckel","year":"1999","journal-title":"Zbl Chir"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/00007890-199505150-00018","article-title":"Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs","volume":"59","author":"Rosengard","year":"1995","journal-title":"Transplantation"},{"key":"B66","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/nm0995-964","article-title":"The generation of transgenic pigs as potential organ donors for humans","volume":"1","author":"Cozzi","year":"1995","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.kint.2016.08.035","article-title":"Renal xenotransplantation: experimental progress and clinical prospects","volume":"91","author":"Wijkstrom","year":"2017","journal-title":"Kidney Int"},{"key":"B68","doi-asserted-by":"publisher","first-page":"11138","DOI":"10.1038\/ncomms11138","article-title":"Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft","volume":"7","author":"Mohiuddin","year":"2016","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-018-0765-z","article-title":"Consistent success in life-supporting porcine cardiac xenotransplantation","volume":"564","author":"Langin","year":"2018","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02306\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T16:45:21Z","timestamp":1664556321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02306\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2019.02306"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02306","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"article-number":"2306"}}